Hypersensitivity to sub-Tenon's topotecan in fibrin adhesive in patients with retinoblastoma.
Sub-Tenon's space delivery of topotecan in a fibrin sealant was used as an adjunct to laser therapy for small retinoblastoma tumors in 25 children (77 injections). We report serious hypersensitivity reactions in 2 children on their third sub-Tenon's injection of topotecan in fibrin sealant. One child subsequently had topotecan in an autologous blood clot with no allergic reaction. Although allergic reaction to topotecan has been reported in the literature, fibrin glue reactions are more common and are likely due to aprotinin hypersensitivity.
Department of Ophthalmology and Visual Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Ophthalmology and Visual Sciences, University of Toronto, Ontario, Canada. Electronic address: tsangpam@gmail.com.
Paulita Pamela P
PP
Astudillo
Princess Margaret Hospital, University Health Network, Toronto, Canada.
Priya
P
Durairaj
Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Pediatrics, University of Toronto, Ontario, Canada.
Helen S L
HS
Chan
Department of Ophthalmology and Visual Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Ophthalmology and Visual Sciences, University of Toronto, Ontario, Canada.
Elise
E
Héon
Department of Ophthalmology and Visual Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Ophthalmology and Visual Sciences, University of Toronto, Ontario, Canada; Princess Margaret Hospital, University Health Network, Toronto, Canada; Department of Medical Biophysics, University of Toronto, Ontario, Canada; Department of Molecular Genetics, University of Toronto, Ontario, Canada.
Brenda L
BL
Gallie
D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002675:Child, Preschool; D003229:Conjunctival Diseases / Q000139:chemically induced / Q000188:drug therapy; D004155:Diphenhydramine / Q000627:therapeutic use; D004337:Drug Carriers; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D015353:Eye Enucleation; D005141:Eyelid Diseases / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D015718:Fibrin Tissue Adhesive; D006801:Humans; D008297:Male; D019572:Retinal Neoplasms / Q000188:drug therapy*; D012175:Retinoblastoma / Q000188:drug therapy*; D058475:Tenon Capsule / Q000187:drug effects; D059004:Topoisomerase I Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects*; D014581:Urticaria / Q000139:chemically induced / Q000188:drug therapy
D018926:Anti-Allergic Agents; D000970:Antineoplastic Agents; D004337:Drug Carriers; D015718:Fibrin Tissue Adhesive; D059004:Topoisomerase I Inhibitors; D019772:Topotecan; D004155:Diphenhydramine